Oral tolerance to cancer can be abrogated by T regulatory cell inhibition

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Whelan, Maria C ^a   Casey, Garrett ^a   Larkin, John O ^a   Guinn, Barbara Ann ^b   O'Sullivan, Gerald C ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; PHOSPHATE BUFFERED SALINE; ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; EFFECTOR CELL; FIBROSARCOMA; FLOW CYTOMETRY; GROWTH RATE; IMMUNOLOGICAL TOLERANCE; INTESTINE CANCER; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; ORAL TOLERANCE; REGULATORY T LYMPHOCYTE; SPLEEN; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TISSUE HOMOGENATE; TISSUE SECTION; TUMOR GROWTH; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CYTOLOGY; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE DEPLETION; METABOLISM; NEOPLASM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84901349978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097602     Document Type: Article

References (22)

1. Micheli A, Baili P, Quinn M, Mugno E, Capocaccia R, et al. (2003) Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas. Ann Oncol 14 Suppl 5: v28-40. (Pubitemid 46417462)
2. Zhang Y (2013) Epidemiology of esophageal cancer. World J Gastroenterol 19: 5598-5606.
3. Weiner HL, da Cunha AP, Quintana F, Wu H (2011) Oral tolerance. Immunol Rev 241: 241-259.
4. O'Brien MG, Collins CG, Collins JK, Shanahan F, O'Sullivan GC (2003) Oral immune tolerance to tumor specific antigens may confer growth advantage to esophageal and gastric cancers. Dis Esophagus 16: 218-223.
5. Wang X, Sherman A, Liao G, Leong KW, Daniell H, et al. (2013) Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 65: 759-773.
6. Faria AM, Weiner HL (1999) Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 73: 153-264. (Pubitemid 29300430)
7. Nishikawa H, Sakaguchi S (2014) Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27C: 1-7.
8. Whelan MC, Casey G, MacConmara M, Lederer JA, Soden D, et al. (2010) Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. Cancer Gene Ther 17: 501-511.
9. Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19: 217-223. (Pubitemid 46356965)
10. Curiel TJ, Barnett B, Kryczek I, Cheng P, Zou W (2006) Regulatory T Cells in Ovarian Cancer: biology and therapeutic potential. Cancer Immunity Vol 6, Suppl 1: p 20.
11. Needham DJ, Lee JX, Beilharz MW (2006) Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 343: 684-691.
12. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, et al. (2007) Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 15: 2194-2202. (Pubitemid 350148937)
13. Larkin J, Tangney M, Collins C, Casey G, O'Brien MG, et al. (2006) Oral immune tolerance mediated by suppressor T cells may be responsible for the poorer prognosis of foregut cancers. Med Hypotheses 66: 541-544.
14. Weiner HL (1997) Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 48: 341-351.
15. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240. (Pubitemid 24291983)
16. Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS (1995) Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 155: 3653-3659.
17. Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F, et al. (1990) Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 144: 1689-1695. (Pubitemid 20093998)
18. Murphy J, O'Sullivan GC, Lee G, Madden M, Shanahan F, et al. (2000) The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival. Am J Gastroenterol 95: 3607-3614.
19. Boncheva V, Bonney SA, Brooks SE, Tangney M, O'Sullivan G, et al. (2013) New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? Cancer Gene Ther 20: 157-168.
20. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, et al. (2008) Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 8: 66-78.
21. Castro-Junior AB, Horta BC, Gomes-Santos AC, Cunha AP, Silva Steinberg R, et al. (2012) Oral tolerance correlates with high levels of lymphocyte activity. Cell Immunol 280: 171-181.
22. Castro-Sanchez P, Martin-Villa JM (2013) Gut immune system and oral tolerance. Br J Nutr 109 Suppl 2: S3-11.